“…For most indications, cytopathological and histopathological assessment should be used in a complementary manner rather than exclusively. Cytopathological methods perform better for the evaluation of nuclear and cellular characteristics, while histopathological assessment of CB and core samples are advantageous over cytopathological assessment in cases in which immunohistochemistry is able to establish a diagnosis, e. g. in non-PDAC, gastrointestinal SETs, rare benign diseases, and lymphadenopathy [94,148,216,221,281,283,290,310,332,340,354,356,361,369,372,650].…”